Despite these limitations, the researchers believe the study confirmed the efficacy and safety of bimekizumab and brodalumab ...

The investigational new drug application for Zabalafin Hydrogel for the treatment of mild to moderate atopic dermatitis has ...

In October 2024, the U.S. Food and Drug Administration (FDA) approved SELARSDI™for all indicationsmatching the reference product ...

Oral, once-daily doses of VYN202 being evaluated in subjects with moderate-to-severe plaque psoriasis Top-line data from the 12-week double-blind trial expected by year-end 2025 Phase 1b trial designe ...

A real-world study in Spain finds faster improvements with induction therapy but highlights long-term drug survival ...

GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative ...

The initial funding will support the completion of their first-in-human trial for diabetic foot ulcers and IND-enabling studies for their psoriasis program. Additionally, FibroBiologics has finalized ...

The overall average body fat percentage in the United States is about 39.9% for women and 28.1% for men, so below these amounts would technically be “below average.” However, most people in the United ...

There are just under a dozen biologics on the market for the treatment of psoriasis, with the majority available in Malaysia. One of the latest to be introduced here is the monoclonal antibody ...

Biologics are more targeted than other psoriasis treatments. They’re also more expensive, and you take them less frequently. Doctors usually prescribe them for moderate to severe psoriasis.